Skip to content
Medical Health Aged Care, National News Current Affairs

New discovery for treatment of primary liver cancer

Monash University 2 mins read
Drug discovery

A preclinical study led by Monash University has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular carcinoma (HCC).

The team of researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) found the drug combination reverses the symptoms of nonalcoholic steatohepatitis (NASH) and, subsequently, markedly reduces the onset of NASH-driven HCC, without affecting the liver in mice.

The study, published in Science Advances, used a mouse model that mimics human NASH-driven HCC to implement a combination treatment of an endoplasmic reticulum (ER) stress inhibitor called ‘BGP-15’ with the inflammation blocker, ‘Olamkicept’. 

Both of these drugs are already proven to be safe in humans and have progressed to Phase 2 and 3 human clinical trials for other metabolic and/or inflammatory diseases. 

The study’s lead author, Professor Mark Febbraio from MIPS, said this is an exciting discovery for a particularly widespread and devastating disease with a low survival rate.

“HCC is increasing at an alarming rate largely due to increased obesity and type 2 diabetes which may lead to NASH, a well known HCC risk factor,” said Professor Febbraio. 

The rise in HCC coincides with patients presenting with obesity and symptoms associated with the metabolic syndrome, especially metabolic dysfunction-associated fatty liver disease (MAFLD). Globally, a staggering 25 per cent of the population are estimated to be living with MAFLD, with around 15 per cent of those exhibiting signs of NASH.

“Despite the high prevalence of NASH and the alarming rise in NASH-driven HCC, there are currently no FDA approved treatments that halt disease progression.

“Given that ER stress and inflammation are hallmarks of NASH-driven HCC, and that BGP-15 and Olamkicept have both already proven to be safe, we tested whether these drugs – as monotherapy, or in combination – would prevent NASH and/or NASH driven HCC in mice.

“Consistent with our hypothesis, the study shows that while monotherapy with either of the two drugs modestly slowed progression, when combined they have shown to be a realistic therapeutic strategy for treating human NASH and progression to HCC, diseases that are rapidly growing with a clinical unmet need.”

Professor Febbraio said that given the significance of the discovery, combined with the urgent need for new safe and effective treatments for NASH and NASH-driven HCC, the team ultimately hope their findings will progress toward clinical trials. 

“We have to stress that this study was performed in mice, not humans. However, as both drugs have been shown to be safe in several human clinical trials, the logical next step is testing the BGP-15/Olamkicept combination in clinical trials for patients with NASH and or HCC.”

https://www.science.org/doi/full/10.1126/sciadv.adh0831?af=R


Contact details:

Kate Carthew - Media and Communications Manager
E: kate.carthew@monash.edu
T: +61 (0) 438 674 814

Media

More from this category

  • Medical Health Aged Care
  • 04/12/2023
  • 09:52
AbbVie

RINVOQ® (upadacitinib) now reimbursed for Australians living with Severe Crohn’s disease1

RINVOQ®, a once daily tablet, has become available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients living with severe active Crohn’s disease (CD)1,2 It’s the first new molecule for CD to be funded by the Government in seven years1,3 Australia has one of the high rates in the world, impacting many in their 20s to 30s-6 Currently there is no cure for CD and severity of the disease is on the rise due to environmental & dietary factors7,8 SYDNEY, AUSTRALIA, 4 December 2023 – AbbVie (NYSE: ABBV), is pleased to announce RINVOQ® (upadacitinib), a once daily tablet, has been…

  • Medical Health Aged Care
  • 04/12/2023
  • 09:47
For immediate release - December, 4 2023

Survey reveals what’s standing in the way of good health

Aussies are being urged to prioritise their health and wellbeing with research revealing more than 40 per cent feel cost or time pressures are the main barrier standing in their way. With the end of year approaching, Australians are being encouraged to make the most from their health insurance and book any medical appointments they might have forgotten or missed in 2023. The Bupa Pulse Check study also revealed that of the 38 per cent of Australians who say they’re struggling to maintain their health and wellbeing, 50 per cent feel cost was a barrier with the survey also showing…

  • Medical Health Aged Care
  • 04/12/2023
  • 00:00
Cube on behalf of Arthritis Australia

Resources launched to alleviate increasing shortfall in arthritis care

Comprehensive care resources set best practice benchmarks to help empower patients to advocate for better management of their disease Arthritis community being ‘left in waiting rooms’ with shortfalls of 302 adult and 41 paediatric rheumatologists [Canberra, Australia] – Arthritis Australia is launching first of a kind resources to equip those living with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) to navigate the management of their diseases against best practice care standards and minimise the impact of shortfalls in clinical care – notably serious shortages of rheumatologists and other rheumatology health professionals. The new resources, created in collaboration with The…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.